Error loading player: No playable sources found

ICH Q9 Risk Management Revision and Practical Applications for ATMPs

Date
October 21, 2021
This product is not available for individual purchase, but it is available as part of the following products:

ICH Q9(R1) – Quality Risk Management (QRM) is currently being revised, and step 2 is expected to be reached by end of 2021. The update of this guideline is anticipated to benefit ATMP by fostering increased use of science based QRM activities.
Advanced therapy medicinal products (ATMPs) are medicines that include a wide range of different products. Due to their complexity, the approaches used in the development, manufacture and control of well characterised biological products may not be fully applicable. A pro-active risk-based approach is essential to drive the product development and determine the extent of quality, non-clinical and clinical data required.
This session will provide an update on ICH Q9 development and discuss the importance of Risk based approaches and QRM in the development of ATMP.

Session Chairs

Speaker Image for Kowid Ho
F. Hoffmann-La Roche Ltd.
Speaker Image for Teresa Pepper
BioMarin U.K. Ltd.
Speaker Image for Tara Sanderson
UCB Pharma Ltd.

Session Speakers

Speaker Image for Kevin O'Donnell
HPRA-Health Products Regulatory Authority
Speaker Image for Adam Walker
GlaxoSmithKline plc
Speaker Image for Andrea Challand
F. Hoffmann-La Roche Ltd.
Speaker Image for Natalie Ward
BioMarin U.K. Ltd.

Related Products

Thumbnail for New Trends in Comparability
New Trends in Comparability
Comparability is a well-established scientific concept that is pivotal to biological product realisation. It successfully enables product development and lifecycle management of existing products and the development of biosimilars…
Thumbnail for Revision of ICH Q2(R1) and the New Guidance
Revision of ICH Q2(R1) and the New Guidance
Efforts are underway to update and expand the applicability of ICH Q2(R1), Validation of Analytical Procedures, the authoritative guidance on analytical method validation…
Thumbnail for Applying Patient-centric Quality Standards Concepts to Biotechnology and Advanced Therapy Products
Applying Patient-centric Quality Standards Concepts to Biotechnology and Advanced Therapy Products
The current practice in establishing specifications as defined in ICH specification guidelines is essentially based solely on clinical experience…